Shi Wei

MD, PhD

Professor of Pathology, Director of the Division of Women’s Health, University of Alabama at Birmingham

Dr. Wei is Professor of Pathology, Director of the Division of Women's Health at the University of Alabama at Birmingham. His major research interests include discovery and evaluation of biomarkers in breast cancer and other malignancies, evaluation of prognostic factors in breast cancer and malignant bone tumors, and tumor bone metastasis. Dr. Wei has published over 300 professional writings in these fields, including more than 180 manuscripts in some of the leading peer-reviewed journals such as JAMA, Journal of Clinical Investigation, and Modern Pathology. He has edited 3 textbooks and contributed 8 monographs in the fields of breast pathology and bone/ soft tissue pathology, recognizing his expertise in these areas. Dr. Wei is the Editor-in-Chief of Human Pathology Reports and editorial board member of several key pathology journals.

“The IHC atlas is a unique tool for healthcare professionals in practice or in training to access evidence-based and peer-led information, and provide a real-time, self-checking opportunity of their cutting-edge knowledge, a feature not available at other sites.”

HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; JAMA, Journal of the American Medical Association.

Resources featuring Dr. Shi Wei

Close Filters Add Filters

Sort by:

Newest to Oldest

Filters:

Resources

Educational courses and supporting
materials, developed by your peers,
to help evolve your clinical practice
of HER2 IHC assessment.

Explore Resources

Shi Wei

Professor of Pathology, Director of the Division of Women’s Health, University of Alabama at Birmingham

Resources

Educational courses and supporting
materials, developed by your peers,
to help evolve your clinical practice
of HER2 IHC assessment.

Quick Links

Breast Cancer Links

Gastric Cancer Links

About Us

Legal

What is a Daiichi Sankyo Company or AstraZeneca authorized person?

Shi Wei

Professor of Pathology, Director of the Division of Women’s Health, University of Alabama at Birmingham

Resources

Educational courses and supporting materials, developed by your peers, to help evolve your clinical practice of HER2 IHC assessment.

Quick Links

Breast Cancer Links

Gastric Cancer Links

About Us

Legal

What is a Daiichi Sankyo Company or AstraZeneca authorized person?

Educational courses and supporting
materials, developed by your peers,
to help evolve your clinical practice
of HER2 IHC assessment.